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Abstract
Background and Objectives—Gender-specific factors associated with stimulant abstinence
severity were examined in a stimulant abusing or dependent residential treatment sample (N=302).
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Method—Bivariate statistics tested gender differences in stimulant abstinence symptoms,
measured by participant-reported experiences of early withdrawal. Multivariate linear regression
examined gender and other predictors of stimulant abstinence symptom severity.
Results—Women compared to men reported greater stimulant abstinence symptom severity.
Anxiety disorders and individual anxiety-related abstinence symptoms accounted for this
difference. African American race/ethnicity was predictive of lower stimulant abstinence severity.
Discussion and Conclusions—Women were more sensitive to anxiety-related stimulant
withdrawal symptoms.
Scientific Significance—Clinics that address anxiety-related abstinence symptoms, which
more commonly occur in women, may improve treatment outcome.
Keywords
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gender; stimulant abstinence severity; early withdrawal symptoms; anxiety

BACKGROUND AND OBJECTIVES
Current U.S. population surveys indicate more general drug use and higher rates of illicit
drug dependence for men than women.1 However, male and female patterns of use and
disorders differ by the specific drug used. Combined annual data from the most recent
National Survey on Drug Use and Health showed no significant gender difference in the
abuse of cocaine.2 Studies suggest that female users exceed males on the severity of
dependence regardless of the stimulant used,3,4 and addiction severity at treatment entry for
drug abuse has been linked to poorer outcomes in clinical samples.5
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Specifically for stimulant abuse, more severe abstinence symptoms have been associated
with early treatment termination and greater problems on the Addiction Severity Index drug
use subscale.6,7 Stimulant abstinence symptoms are signs of early withdrawal and include
sleep and eating disturbances, anxiety, and depression.7 The relationship of gender to
stimulant abstinence symptoms and the specific factors associated with stimulant abstinence
symptom severity are not well described. This secondary analysis examined gender
characteristics among baseline participants in a multisite randomized clinical trial testing the
addition of vigorous exercise compared to health education as a treatment strategy for
stimulant abuse or dependence. Our central aim was to test gender differences in stimulant
abstinence symptom severity, as well as the demographic, drug use, and psychiatric factors
associated with more severe stimulant abstinence symptoms.
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METHODS
Participants
Participants (women n = 121 and men n = 181) were from the Stimulant Reduction
Intervention using Dose Exercise (STRIDE) trial, a National Institute on Drug Abuse
Clinical Trials Network study (CTN-0037). Full details about the protocol are described
elsewhere.8 Briefly, recruitment occurred during residential treatment in nine geographically
diverse community treatment programs that had a 21- to 30-day residential length of stay

Am J Addict. Author manuscript; available in PMC 2016 June 01.

Chartier et al.

Page 3

Author Manuscript

and post-residential outpatient services. Eligible participants reported illicit stimulant drug
use (e.g., cocaine, methamphetamine, or amphetamine) in the 30 days prior to residential
treatment program (RTP) entry and received medical clearance for exercise. Individuals
with an opioid dependence diagnosis, general medical conditions that contraindicated
exercise, and those with psychosis or other psychiatric conditions that posed a potential
safety risk were excluded. Participants provided informed consent.
Measures
All measures utilized for the STRIDE trial were described in Trivedi et al., 2011.8
Demographic variables included age, race/ethnicity, level of education, employment status,
and marital status.
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The Addiction Severity Index-Lite (ASI-Lite) provided lifetime measures of years of
primary stimulant use (cocaine, amphetamine, or methamphetamine) and assessed problems
associated with drug use in seven domains: medical, employment, alcohol, drug use, legal,
family/social, and psychiatric. The Timeline Followback (TLFB) measured days of
stimulant use in the 30 days prior to RTP entry.
The Composite International Diagnostic Interview (CIDI) was used to determine stimulant
use disorders (categorized here as: cocaine only, cocaine and other stimulants, or other
stimulants--not cocaine--only), as well as other substance use disorders using Diagnostic
and Statistical Manual-IV (DSM-IV) criteria. The Fagerstrom Test for Nicotine Dependence
(FTND) measured current nicotine dependence intensity.

Author Manuscript

The Mini International Neuropsychiatric Interview (MINI) measured DSM-IV psychiatric
disorders, including major depression, dysthymia, mania, post-traumatic stress disorder
(PTSD), panic disorder, social phobia, and obsessive compulsive disorder (OCD).
The Stimulant Selective Severity Assessment (SSSA; based on the Cocaine Selective
Severity Assessment (CSSA)) measured self-reported stimulant abstinence symptom severity
for the past 24 hours.7 The SSSA covered cocaine, methamphetamine, and other stimulants.
Domains included carbohydrate craving, mood, appetite, sleep, energy, and pulse rate.
Participants indicated the frequency or intensity of their withdrawal experiences for 16
individual symptoms on a scale of 0 to 7, including, for example, anxiety (i.e., 0 usually
doesn't feel anxious; 3-4 anxious half the time; and 7 anxious all the time) and irritability
(i.e., 0 most things are not irritating; 3-4 many things are irritating; and 7 mostly everything
is irritating or upsetting). The CSSA stimulant craving items were not included in this SSSA
measure.
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Analysis
Bivariate tests for gender comparisons on sample characteristics were conducted using chisquare and t tests, for categorical and continuous variables, respectively. A multivariate
linear regression model tested the relationship of gender to stimulant abstinence symptom
severity while controlling for other variables. Gender and variables found to be significant
(p < .05) on bivariate tests were entered into the regression model simultaneously. ASI
subscales were not included because of the overlap with other more informative variables
Am J Addict. Author manuscript; available in PMC 2016 June 01.
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(e.g., the psychiatric problems subscale versus specific psychiatric diagnoses). For the
modelled days of cocaine and methamphetamine use variables, we set days of use for nonusers to zero. Non-users were participants who responded ‘no’ to screening questions for
any past-30 day cocaine or methamphetamine use. Diagnostics showed that normality and
other standard assumptions for linear regression were met.
To further characterize the relationship between gender and stimulant abstinence symptom
severity, two post hoc analyses were conducted. First, one variable at a time was removed
from the linear regression model to examine the change in the relationship between gender
and abstinence symptom severity. We removed comorbid psychiatric diagnosis variables
with the smallest p-values. Additionally, t tests were conducted for gender and each
individual abstinence symptom item.
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RESULTS
Gender characteristics
On demographic variables, women were younger than men, M=35.67 (SD=9.9) versus
M=41.17 (SD=10.8) years, and more likely to be Hispanic, 17.36% versus 5.52%, p-values
< .001. Men were more likely to have a high school degree or more education (86.19%
versus 74.38%, p=.023) and to be employed (39.23% versus 19.83%) and African American
(51.93% versus 29.75%), p-values < .001.
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Table 1 shows gender comparisons on measures of stimulant drug use, drug use problems,
and comorbid drug use and psychiatric disorders. Men reported more years using stimulants
as their primary drug. Women reported higher median cocaine and methamphetamine use
days prior to RTP entry, and were more likely to report dual stimulant use disorders (cocaine
use disorder plus another non-cocaine stimulant use disorder). Most men met the diagnosis
for a cocaine use disorder only. Women had higher ASI subscale scores on employment,
family/social, and psychiatric problems, while men had higher scores for alcohol problems.
Men were also more likely to be diagnosed with alcohol dependence as well as marijuana
dependence, and had greater nicotine dependence intensity. Women had a higher prevalence
of current manic episode, panic disorder, and OCD diagnoses.
Stimulant abstinence symptom severity

Author Manuscript

On the SSSA, women reported greater stimulant abstinence symptom severity compared to
men (Table 1). In the multivariate model, gender was no longer associated with abstinence
symptom severity, p-value > .05. Model results are presented in Table 2. African American
race/ethnicity was associated with lower abstinence symptom severity than non-African
Americans after controlling for other variables in the model. Other modelled variables were
non-significant; however, after two variables were removed from the model, i.e., 1) panic
disorder and 2) OCD diagnoses, gender was associated with a higher stimulant abstinence
severity score compared to men. Post hoc tests also identified higher scores for women on
four individual abstinence symptoms, including anxiety (men: M=1.02, SD=1.7; women:
M=1.74, SD=2.1, p=.001), tension (men: M=0.72, SD=1.5; women: M=1.09, SD=1.8, p=.
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047), attention (men: M=0.62, SD=1.4; women: M=1.12, SD=1.9, p=.008), and irritability
(men: M=0.80, SD=1.4; women: M=1.55, SD=2.1, p<.001).

DISCUSSION AND CONCLUSIONS
We identified differences between men and women on measures of stimulant use and
associated disorders. Women were more likely to report dual stimulant use disorders (i.e.,
cocaine and other stimulant use disorders), while most men met diagnosis for a cocaine use
disorder only. These dual stimulant diagnoses corresponded with both more
methamphetamine use days and more cocaine use days for women than men. Preclinical and
clinical studies provide some evidence to indicate that women, via increased estrogen levels,
are more vulnerable to the reinforcing effects of stimulant drugs.9
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Women reported greater drug use problems in employment, family/social, and psychiatric
domains compared to men. Men reported greater problems related to alcohol and were more
likely to have an alcohol dependence diagnosis. This is consistent with other studies
involving stimulant abusers, with women reporting more employment and economic issues
and men more alcohol problems.10,11 Women in treatment also report significantly greater
depressive symptomatology and a history of abuse and violence in their lives,10,5 although
in the current study, major depression, dysthymia, and PTSD were not significantly different
in men and women.
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We found greater stimulant abstinence symptom severity in women compared to men. More
severe early withdrawal symptoms appeared to be positively associated with anxiety-related
symptoms (e.g., anxiety, tension, difficulty concentrating, and irritability), and panic
disorder and OCD diagnoses appeared to account for the association between gender and
stimulant abstinence symptom severity. Being African American was negatively associated
with stimulant abstinence symptom severity. African Americans in the STRIDE sample,
relative to other racial/ethnic groups, were majority male, reported better mental health
status, and had low psychiatric comorbidity,12 which may help describe our findings here.
Women may be more sensitive to the anxiety-related stimulant withdrawal symptoms.
STRIDE women compared to men reported higher rates of anxiety-related disorders (i.e.,
panic disorder and obsessive compulsive disorder). Greater psychological severity in women
is associated with poorer treatment retention and outcomes.5 Individuals who remain
anxious during treatment may be at greater risk for using substances to reduce anxiety
symptoms.13
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There were some limitations to this study, including the retrospective assessment of drug
use, drug use problems, and drug and psychiatric disorders. Self-report measures may be
subject to recall bias (e.g., years of primary stimulant use), although most time periods
assessed were relatively short (e.g., 24 hours and past 30 days for the SSSA and TLFB,
respectively). The generalizability of our findings may be limited by the trial's sampling
criteria. In particular, eligible participants agreed to participate in a clinical trial and were
medically cleared and willing to exercise.
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SCIENTIFIC SIGNIFICANCE
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Addiction severity at treatment entry is associated with treatment retention and abstinence
outcomes. The CSSA is one measure of stimulant abstinence severity that has been shown to
predict attrition from treatment,6 and could be used by clinic staff during the admissions
process to identify and target stimulant abusing patients with greater risk for poor treatment
outcomes. It is a brief self-administered measure, which potentially makes it well adaptable
to a clinical setting. It could also be an effective tool for identifying specific symptoms (e.g.,
anxiety, tension, and irritability) to discuss with patients in treatment sessions. This study
emphasized anxiety-related withdrawal experiences as salient topics for clinicians to address
in treatment to reduce stimulant abstinence symptoms and potentially the risk for relapse to
substance use. Mood and anxiety disorders are more prevalent in women and non-Hispanic
whites.14 There are mixed findings related to gender and treatment retention,5 but women
who complete stimulant treatment are reported to have similar or better outcomes than
men.15 Future prospective studies could help clarify the relationships we identified between
gender, race/ethnicity, stimulant abstinence symptom severity, and associated anxietyrelated factors.
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Sample Characteristics and Stimulant Abstinence Symptom Severity by Gender
Baseline variables

Total M (SD) or % N =
302

Male M (SD) or % n =
181

Female M (SD) or % n =
121

p

11.14 (9.3)

13.42 (10.9)

9.14 (7.1)

0.012

9.00

8.00

11.00

0.002

12.00

9.50

20.00

0.006

Drug Use Characteristics
Years of Primary Stimulant Use
Days of Cocaine Use (TLFB)

a

Days of Methamphetamine Use (TLFB)

b

Drug Use Diagnoses (CIDI)
Stimulant Use Disorders (%)

0.001

Author Manuscript

    Cocaine only

58.80

65.75

48.33

    Cocaine and other stimulant

30.56

28.18

34.17

    Other stimulant (not cocaine)

10.63

6.08

17.50

Alcohol Dependence (%)

50.33

57.46

39.67

0.002

Marijuana Dependence (%)

31.89

36.46

25.00

0.037

Alcohol

0.21 (0.2)

0.26 (0.3)

0.13 (0.2)

< 0.001

Drugs

0.17 (0.1)

0.16 (0.1)

0.17 (0.1)

0.454

Employment

0.71 (0.3)

0.67 (0.3)

0.76 (0.3)

0.006

Family/Social

0.22 (0.2)

0.20 (0.2)

0.25 (0.2)

0.046

Legal

0.14 (0.2)

0.13 (0.2)

0.15 (0.2)

0.441

Medical

0.16 (0.3)

0.15 (0.3)

0.18 (0.3)

0.373

Psychiatric

0.27 (0.2)

0.22 (0.2)

0.34 (0.2)

< 0.001

3.45 (2.1)

3.76 (2.2)

3.02 (1.8)

0.011

Drug Use Problems (ASI-Lite)

Nicotine Dependence Intensity (FTND)
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Comorbid Psychiatric Diagnoses (MINI)
Major Depressive Episode (%)

22.85

19.34

28.10

0.076

Dysthymia (%)

9.44

11.64

5.75

0.137

Manic Episode (%)

4.97

2.76

8.26

0.031

Post-traumatic Stress Disorder (%)

9.60

8.29

11.57

0.343

Panic Disorder (%)

6.02

3.31

10.17

0.015

Social Phobia (%)

10.93

10.50

11.57

0.770

5.96

3.31

9.92

0.018

11.77 (11.5)

10.44 (11.1)

13.78 (11.9)

0.013

Obsessive Compulsive Disorder (%)
Stimulant Abstinence Severity
SSSA Score

Notes: TLFB = Timeline Followback; CIDI = Composite International Diagnostic Interview; ASI = Addiction Severity Index; FTND = Fagerstrom
Test for Nicotine Dependence; MINI = Mini International Neuropsychiatric Interview; SSSA = Stimulant Selective Severity Assessment;
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a

Median days of use computed for those who used cocaine in the 30 days prior to residential treatment program (RTP) entry (Men n = 157 and
Women n = 82); and
b

Median days of use computed for those who used methamphetamine in the 30 days prior to RTP entry (Men n = 38 and Women n = 43).
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Regression Analysis for Gender and other Variables Predicting Stimulant Abstinence Symptom Severity
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B

SE

p

Gender

2.710

1.5

0.071

Age

0.014

0.1

0.847

High School or more Education

0.101

0.3

0.766

Employed

0.682

1.5

0.642

African American

−4.651

1.6

0.005

Hispanic

−2.994

2.3

0.202

Years of Primary Stimulant Use

−0.020

0.1

0.820

Days of Cocaine Use

−0.047

0.1

0.553

Days of Methamphetamine Use

−0.046

0.1

0.647

Alcohol Dependence

2.155

1.4

0.119

Marijuana Dependence

1.015

1.5

0.485

Nicotine Dependence Intensity

0.519

1.5

0.722

Manic Episode

3.450

3.2

0.288

Panic Disorder

5.636

3.2

0.076

Obsessive Compulsive Disorder (OCD)

4.545

2.9

0.119

Notes. A follow-up analysis, showed that gender (B=3.23, SE=1.5, p=.031) was associated with abstinence symptom severity after two variables
were removed from the model, i.e., 1) panic disorder and 2) OCD.
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